
    
      This study is randomized, prospective, double-blind, placebo-controlled, phase 3 study
      evaluating the prevention of moderate to severe chronic GVHD in patients undergoing bone
      marrow or peripheral blood stem cell transplantation from matched, unrelated donors for acute
      leukemia and myelodysplastic syndrome during the first year after transplant.

      Patients meeting all the inclusion and none of the exclusion criteria will be randomized
      (1:1). All patients will receive premedication and study drug 3 days prior to
      transplantation.
    
  